An advance toward a flu-fighting nasal spray

September 12, 2012
An advance toward a flu-fighting nasal spray

In an advance toward development of a nasal spray that protects against infection with influenza and spread of the disease, scientists are reporting identification of a substance that activates the first-line defense system against infection inside the nose. They describe effects of a synthetic form of a natural substance found in bacterial cell walls in ACS' journal Molecular Pharmaceutics.

David C. Jackson and colleagues explain that the body's so-called innate immune system forms a first-line defense system against respiratory diseases like influenza A—which causes up to 1 billion infections and 500,000 deaths during seasonal epidemics. Those defenses swing into action almost immediately when viruses enter the nose and begin launching an infection. Scientists have been looking for ways to jump-start those defenses during , and Jackson's team turned to Pam2Cys. That synthetic lipoprotein, a substance consisting of a fat and a protein, has shown promise in activating the .

The team found in laboratory tests that using Pam2Cys as a nasal spray primes the body's immune system to fight infections. Importantly, they showed that the compound encourages but does not replace a normal immune response, which has been a concern about some anti-viral medicines. Because Pam2Cys stimulates the immune system against a wide spectrum of viral and bacterial attacks, the authors suggest it may be a particularly useful agent against pandemics and emerging .

Explore further: Both innate and adaptive immune responses are critical to the control of influenza

More information: "Intranasal Administration of the TLR2 Agonist Pam2Cys Provides Rapid Protection against Influenza in Mice" Mol. Pharmaceutics, 2012, 9 (9), pp 2710–2718. DOI: 10.1021/mp300257x

Abstract
The protective role played by the innate immune system during early stages of infection suggests that compounds which stimulate innate responses could be used as antimicrobial or antiviral agents. In this study, we demonstrate that the Toll-like receptor-2 agonist Pam2Cys, when administered intranasally, triggers a cascade of inflammatory and innate immune signals, acting as an immunostimulant by attracting neutrophils and macrophages and inducing secretion of IL-2, IL-6, IL-10, IFN-γ, MCP-1 and TNF-α. These changes provide increased resistance against influenza A virus challenge and also reduce the potential for transmission of infection. Pam2Cys treatment also reduced weight loss and lethality associated with virulent influenza virus infection in a Toll-like receptor-2-dependent manner. Treatment did not affect the animals' ability to generate an adaptive immune response, measured by the induction of functional influenza A virus-specific CD8+ T cells following exposure to virus. Because this compound demonstrates efficacy against distinct strains of influenza, it could be a candidate for development as an agent against influenza and possibly other respiratory pathogens.

Related Stories

Both innate and adaptive immune responses are critical to the control of influenza

June 28, 2012
Both innate and adaptive immune responses play an important role in controlling influenza virus infection, according to a study, published in the Open Access journal PLoS Computational Biology, by researchers from Oakland ...

Flu helps spread pneumonia

April 11, 2011
Bacteria that cause pneumonia and meningitis are only able to spread when individuals are infected with flu, says a scientist reporting at the Society for General Microbiology's Spring Conference in Harrogate. The work could ...

Boosting the aged immune response to flu virus

November 21, 2011
As people age, their immune system becomes less robust. This makes them more susceptible to serious and frequently life-threatening infections with viruses that affect the respiratory tract such as influenza A virus (IAV). ...

Recommended for you

Drug for spinal muscular atrophy prompts ethical dilemmas, bioethicists say

December 11, 2017
When the Food and Drug Administration approved the first drug for people with spinal muscular atrophy a year ago, clinicians finally had hope for improving the lives of patients with the rare debilitating muscular disease. ...

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.